Palliative radiotherapy as treatment for non-resectable soft tissue sarcomas in the dog - a report of 15 cases

被引:16
|
作者
Plavec, T.
Kessler, A.
Kandel, B.
Schwietzer, A.
Roleff, S.
机构
[1] Univ Ljubljana, Clin Small Anim Med & Surg, Fac Vet, Ljubljana 1000, Slovenia
[2] Hofheim Vet Hosp, Hofheim Am Taunus, Germany
关键词
cobalt(60); dog; palliative radiotherapy; soft tissue sarcoma;
D O I
10.1111/j.1476-5810.2006.00097.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Fifteen dogs with various non-resectable soft tissue sarcomas were treated with a palliative protocol of Cobalt(60) radiation. Twelve (80%) of the 15 tumours were fibrosarcomas and haemangiopericytomas. Total tumour radiation dose was 24 Gy, given in three 8 Gy fractions, on days 0, 7, 21 or weekly. Thirteen tumours (87%) responded with stable disease; median time to progression and median survival time were 263 and 332 days, respectively. Radiation toxicity was negligible. The survival and local control with this palliative protocol are almost comparable with curative intent primary radiotherapy.
引用
收藏
页码:98 / 103
页数:6
相关论文
共 50 条
  • [1] Chemotherapy options for advanced non-resectable soft tissue sarcomas in adults
    Schuette, J.
    Hartmann, J. T.
    ONKOLOGE, 2009, 15 (04): : 404 - 414
  • [2] RADIOTHERAPY WITH PIONS FOR NON-RESECTABLE SOFT-TISSUE SARCOMAS AT THE SWISS-INSTITUTE-FOR-NUCLEAR-RESEARCH (SIN)
    THUM, P
    GREINER, R
    BLATTMANN, H
    CORAY, A
    ZIMMERMANN, A
    STRAHLENTHERAPIE UND ONKOLOGIE, 1988, 164 (12): : 714 - 723
  • [3] A phase II study of tivozanib in patients with metastatic and non-resectable soft tissue sarcomas
    Agulnik, Mark
    Milhem, Mohammed M.
    Rademaker, Alfred
    Humphreys, Catherine
    Abbinanti, Susan E.
    Nye, Lauren Elizabeth
    Cehic, Rasima
    Polish, Ariel
    Vintilescu, Claudia Roxana
    McFarland, Thomas
    Skubitz, Keith M.
    Robinson, Steven Ian
    Okuno, Scott H.
    Van Tine, Brian Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Isolated limb perfusion in non-resectable soft tissue sarcomas of the limbs: experience in el Bajio
    Tavares-de la Paz, Alberto
    Martinez-Said, Hector
    Vaca-Perez, Enrique
    Angel Guerrero-Ramos, Miguel
    Esparza-Perez, Hiram
    GACETA MEXICANA DE ONCOLOGIA, 2013, 12 (02): : 73 - 80
  • [5] Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas
    Schulte, Brian
    Mohindra, Nisha
    Milhem, Mohammed
    Attia, Steven
    Robinson, Steven
    Monga, Varun
    Hirbe, Angela C.
    Oppelt, Peter
    Charlson, John
    Helenowski, Irene
    Abbinanti, Susan
    Cehic, Rasima
    Okuno, Scott
    Van Tine, Brian A.
    Agulnik, Mark
    BRITISH JOURNAL OF CANCER, 2021, 125 (04) : 528 - 533
  • [6] Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas
    Brian Schulte
    Nisha Mohindra
    Mohammed Milhem
    Steven Attia
    Steven Robinson
    Varun Monga
    Angela C. Hirbe
    Peter Oppelt
    John Charlson
    Irene Helenowski
    Susan Abbinanti
    Rasima Cehic
    Scott Okuno
    Brian A. Van Tine
    Mark Agulnik
    British Journal of Cancer, 2021, 125 : 528 - 533
  • [7] Pubectomy and stereotactic radiotherapy for the treatment of a non-resectable sacral osteosarcoma causing pelvic canal obstruction in a dog
    Randall, Victoria D.
    Boston, Sarah E.
    Gardner, Heather L.
    Griffin, Lynn
    Oblak, Michelle L.
    Kubicek, Lyndsay
    CANADIAN VETERINARY JOURNAL-REVUE VETERINAIRE CANADIENNE, 2016, 57 (09): : 945 - 949
  • [8] Preoperative radiotherapy in the treatment of soft tissue sarcomas
    Virkus, WW
    Mollabashy, A
    Reith, JD
    Zlotecki, RA
    Berrey, BH
    Scarborough, MT
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2002, (397) : 177 - 189
  • [9] Chemotherapieoptionen bei fortgeschrittenen, irresektablen Weichteilsarkomen des ErwachsenenChemotherapy options for advanced non-resectable soft tissue sarcomas in adults
    J. Schütte
    J.T. Hartmann
    Der Onkologe, 2009, 15 (4): : 404 - 414
  • [10] A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
    Agulnik, Mark
    Mohindra, Nisha Anjali
    Milhem, Mohammed M.
    Attia, Steven
    Robinson, Steven Ian
    Rademaker, Alfred
    Abbinanti, Susan E.
    Cehic, Rasima
    Humphreys, Catherine
    Prudner, Bethany
    Okuno, Scott H.
    Van Tine, Brian Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)